BMEA
Biomea Fusion, Inc.Healthcare·Biotechnology
$1.38
$82M market cap
Revenue
$0.0M
Free Cash Flow
$-24.9M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
2-Year Price History
$1.42-65.7%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -12.7 | -12.8 | -12.4 | -11.7 | -11.7 | -0.0 | 44.7 | 1.2 | 72.3 | <-999% | -- | -- |
| Act | 2025-Q4 | 0.0 | -11.7 | -11.7 | 4.6 | -13.2 | -13.2 | -0.0 | 55.8 | 1.6 | 72.3 | -418.9% | -- | -- |
Valuation & Metrics
Market Stats
Price$1.38
Market Cap$82M
Enterprise Value$39M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-30.3%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-7.8M
Free Cash Flow$-24.9M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-2271.4%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares14.4M
Days to Cover8.0
Change (vs Prior)+1.9%
Need at least 2 settlement dates for chart
Employees
Headcount79
Revenue / Employee$0
Gross Profit / Employee$-1,177
Cash Runway
21.6months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
35.0%(-9.1% YoY)
49 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
8.6%(-4.7% YoY)
9 filers
Vanguard, iShares, SPDR
Market makers
1.9%(+1.6% YoY)
5 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| FMR LLC | $13.5M | $16.04 | +$0 | +$5.2M | -0.0% | $1.89T |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $4.0M | $1.53 | +$4.0M | +$4.0M | — | $4.04T |
| Aisling Capital Management LP | $3.1M | $1.80 | +$0 | +$1.9M | +5.6% | $476M |
| RENAISSANCE TECHNOLOGIES LLC | $2.0M | $2.95 | +$1.3M | +$1.6M | +1.2% | $63.91B |
| MARSHALL WACE, LLP | $1.8M | $4.46 | +$58K | +$1.8M | +0.6% | $92.71B |
| CITADEL ADVISORS LLC | $1.0M | $6.37 | +$730K | +$956K | -0.4% | $138.22B |
| Mariner, LLC | $1.0M | $1.56 | +$105K | +$1.0M | -0.1% | $85.47B |
| BlackRock, Inc.Passive | $981K | $9.58 | +$14K | −$2.3M | -0.2% | $5.69T |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $964K | $9.49 | +$232K | +$885K | -0.6% | $77.14B |
| FIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A. | $852K | $1.24 | −$114K | +$852K | +4.2% | $2.85B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $839K | $10.92 | −$23K | −$119K | +2.3% | $1.61T |
| XTX Topco Ltd | $812K | $2.01 | +$412K | +$812K | -1.9% | $5.74B |
| UBS Group AG | $789K | $5.96 | +$208K | +$426K | -0.3% | $562.11B |
| TWO SIGMA INVESTMENTS, LP | $595K | $7.52 | −$53K | −$128K | -0.9% | $117.03B |
| MORGAN STANLEY | $531K | $11.87 | −$40K | −$204K | -0.3% | $1.65T |
| VANGUARD FIDUCIARY TRUST COPassive | $514K | $1.53 | +$514K | +$514K | — | $395.83B |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $475K | $3.02 | +$173K | +$475K | +0.4% | $23.79B |
| JANE STREET GROUP, LLCMM | $422K | $10.28 | +$315K | +$386K | -0.1% | $92.10B |
| SUPERSTRING CAPITAL MANAGEMENT LP | $383K | $3.15 | +$0 | +$383K | -1.0% | $140M |
| NORTHERN TRUST CORPPassive | $320K | $13.49 | +$0 | −$136K | -0.2% | $755.34B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+0.67%
avg per quarter
Holders (ex-self)
+0.73%
excl. this stock
Buyers (this Q)
+0.10%
28 buyers · $0.01B in
Sellers (this Q)
-1.99%
15 sellers · $0.00B out
alpha coverage: 88% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-7.6%
how holders react when this stock falls
On quiet Qs
+16.2%
−10% to +10% baseline
On rallies (+10%+)
-4.3%
how they react when this stock rises
Holders' portfolio flow this Q
+3.6%
inflows — adds are organic
Sellers' portfolio flow this Q
-9.4%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-6.9%
Holder mid (any stock)
-5.2%
Holder rally (any stock)
-5.1%
Biggest decreases this quarter
Woodline Partners LPexited−$1.6MFIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A.−$114Kα+4.2Sculptor Capital LPexited−$105KJain Global LLCexited−$68KTWO SIGMA INVESTMENTS, LP−$53Kα-0.9MORGAN STANLEY−$40Kα-0.3GEODE CAPITAL MANAGEMENT, LLC−$23Kα+2.3Point72 Asset Management, L.P.exited−$21KPinnacle Wealth Planning Services, Inc.exited−$4KBANK OF AMERICA CORP /DE/exited−$2K
New buyers this quarter
Top-5 holders · 65.7%
FMR LLC--
VANGUARD CAPITAL MANAGEMENT LLC--
Aisling Capital Management LP--
RENAISSANCE TECHNOLOGIES LLC--
MARSHALL WACE, LLP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
FMR LLC8.8MCormorant Asset Management, LLC—JANUS HENDERSON GROUP PLC—BAKER BROS. ADVISORS LP—ADAGE CAPITAL PARTNERS GP, L.L.C.—Laurion Capital Management LP—Rock Springs Capital Management LP—Boxer Capital, LLC—DRIEHAUS CAPITAL MANAGEMENT LLC—Aisling Capital Management LP2.0M
Analyst Coverage
Analyst Coverage
Analyst Ratings
10
3
Buy: 10Hold: 3Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$197K
4 txns · 2 insiders · 180,000 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2025-12-11 | BUY | Erdtmann Rainer M | director, officer: See Remarks | 30,000 | $1.43 | $43K | $1.04M |
| 2025-12-02 | BUY | Hitchcock Michael J.M. | director, officer: Interim CEO | 100,000 | $0.99 | $99K | $114K |
| 2025-12-01 | BUY | Erdtmann Rainer M | director, officer: See Remarks | 10,000 | $1.05 | $11K | $728K |
| 2025-11-28 | BUY | Erdtmann Rainer M | director, officer: See Remarks | 40,000 | $1.10 | $44K | $752K |
Order Flow (FINRA, ~3w lag)
34.2%retail-2.7pp
12.5%dark+2.3pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Biomea Fusion, Inc.: A Dilution Death-Spiral in a Clinical-Stage Vacuum
Overall Risk
9/10
Fraud
3/10
Dilution
10/10
Insolvency
9/10
Earnings Overstated
4/10
Hidden Liabilities
6/10
Legal
2/10
Audit Warnings
10/10
Hidden Upside
2/10
Contextually Acceptable
4/10